Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price raised by Leerink Partners from $835.00 to $997.00 in a research report released on Monday,Benzinga reports. They currently have a market perform rating on the biopharmaceutical company’s stock.
Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. upped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the stock an “overweight” rating in a report on Friday. Citigroup lifted their target price on shares of Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the company a “neutral” rating in a report on Friday. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a research report on Tuesday, July 7th. Zacks Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Finally, Piper Sandler raised their price target on Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an “overweight” rating in a research report on Monday, October 19th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $898.97.
Check Out Our Latest Stock Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Trading Up 3.6%
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s revenue for the quarter was up 36.3% on a year-over-year basis. During the same period last year, the business earned $11.83 earnings per share. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 49.10 earnings per share for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be paid a dividend of $0.94 per share. The ex-dividend date is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.29%.
Insider Buying and Selling at Regeneron Pharmaceuticals
In related news, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the completion of the transaction, the insider owned 47,833 shares of the company’s stock, valued at $36,960,559.10. This trade represents a 7.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,093 shares of company stock worth $6,506,845 over the last ninety days. Company insiders own 6.97% of the company’s stock.
Institutional Investors Weigh In On Regeneron Pharmaceuticals
A number of hedge funds have recently added to or reduced their stakes in REGN. BlackRock Inc. acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $5,682,636,000. Legal & General Group Plc acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $473,872,000. Bank of New York Mellon Corp acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $472,950,000. Deutsche Bank AG acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $323,249,000. Finally, Man Group plc purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $272,460,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.
Key Stories Impacting Regeneron Pharmaceuticals
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: Q3 results significantly exceeded expectations. Regeneron reported revenue of $5.12 billion, up 36.3% year over year, and non-GAAP EPS of $20.07—23.5% above consensus. The performance was supported by core brands and a larger Sanofi profit share. REGN Q3 deep dive: pipeline progress and core brands drive outperformance
- Positive Sentiment: Analysts raised targets after the earnings beat. Guggenheim increased its target to $1,100, JPMorgan to $1,050, Bank of America to $1,030, and Truist to $982, with buy or overweight ratings. Reports said targets across the analyst group reached as high as $1,175. These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results
- Positive Sentiment: RBC characterized the quarter as evidence of “strong commercial” momentum and a healthy core business, supporting the view that Regeneron’s growth extends beyond a single product or one-time factor. Regeneron’s Strong Commercial Q3 Underscores Core Business Health
- Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable December 3, equivalent to a $3.76 annualized payout and an approximate 0.4% yield.
- Neutral Sentiment: Management will participate in upcoming Jefferies, Evercore and Citi healthcare conferences, giving investors additional opportunities to hear updates on the pipeline and commercial outlook. Regeneron Announces Investor Conference Presentations
- Negative Sentiment: Not all analysts see further gains at the current valuation. Bernstein, Morgan Stanley, RBC, Wells Fargo and Baird maintained market-perform, equal-weight or neutral ratings with targets below the recent share price, highlighting potential near-term downside.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.
Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.
Further Reading
- Five stocks we like better than Regeneron Pharmaceuticals
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
